Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,127
datasets available to search
ShareScore release 0.9.0
Dataset results
1,127 results for “cancer immunotherapy”
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT02133196. IPD Sharing: YES. Countries: 1. Publications: 3.
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
ClinicalTrials.gov study NCT06173986. IPD Sharing: NO. Countries: 1. Publications: 9.
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed
ClinicalTrials.gov study NCT03444753. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
ClinicalTrials.gov study NCT05929768. IPD Sharing: Not stated. Countries: 3. Publications: 0.
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
ClinicalTrials.gov study NCT03122496. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00455572. IPD Sharing: YES. Countries: 6. Publications: 1.
Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients
ClinicalTrials.gov study NCT04203095. IPD Sharing: UNDECIDED. Countries: 1. Publications: 17.
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
ClinicalTrials.gov study NCT00133224. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer
ClinicalTrials.gov study NCT00795977. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Exercise as a Tool to Improve Response to Immunotherapy in Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT07267000. IPD Sharing: UNDECIDED. Countries: 1. Publications: 6.
A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer
ClinicalTrials.gov study NCT05338060. IPD Sharing: NO. Countries: 1. Publications: 22.
Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine
ClinicalTrials.gov study NCT02178670. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
ClinicalTrials.gov study NCT04357873. IPD Sharing: NO. Countries: 1. Publications: 2.
Immunotherapy for Third Line Metastatic Colorectal Cancer
ClinicalTrials.gov study NCT04444622. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer
ClinicalTrials.gov study NCT03047616. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: A systematic review
<p><b>Objectives:</b> Use of immune checkpoint inhibitors (ICIs) as first-line treatment for advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) remains controversial. Clinical trials comparing single-drug immunotherapy (IO) with immunotherapy plus chemotherapy (IC) are lacking. We aimed to compare the efficacy of IO alone with that of IC as first-line treatment for advanced NSCLC.</p> <p><b>Design: </b>Systematic review</p> <p><b>Data sources: </b>PubMed, the Cochrane Library, and Embase for related studies on NSCLC; ClinicalTrials.gov, American Society of Clinical Oncology Meeting Library, and World Conference on Lung Cancer for relevant conference abstracts.</p> <p><b>Eligibility criteria: </b>Articles<b> </b>meeting the following<b> </b>criteria were selected: (1) randomized controlled trials on NSCLC treatment, (2) all individuals in the studies had not received treatment previously, and (3) research on IO monotherapy using programmed death-1/programmed death ligand-1 (PD-L1) inhibitors or IC.</p> <p><b>Data extraction and synthesis:</b> After reading the original literature, two reviewers independently extracted the relevant information. The primary outcomes were progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). We also extracted data on treatment-related adverse events and immune-related adverse events (irAEs).</p> <p><b>Results:</b> Overall, 10 randomized controlled clinical trials (n = 5765) were included. As first-line treatment for advanced NSCLC, IC tended to yield better PFS, OS, and ORR than did IO. Furthermore, IC yielded significantly better PFS than IO when tumor PD-L1 expression was at least 50% (HR: 1.81, 95% CI: 1.18–2.78) and yielded a better OS and PFS when tumor PD-L1 expression was at least 1%; IO resulted in fewer adverse events than did IC. However, the incidence of irAEs was higher for IO than for IC.</p> <p><b>Conclusions:</b> The findings of the indirect comparison indicate that IC as first-line treatment for advanced NSCLC is significantly more effective than IO in patients with PD-L1 expression in at least 50% of tumor cells.</p>
Immuno-transcriptomic profiling of blood and tumor tissue identifies gene signatures associated with immunotherapy response in metastatic bladder cancer
<p>The dataset contains RNA-sequencing data (raw fastq files, not trimmed) of whole blood and whole bladder tissue samples and metadata file with sample annotation. The samples have been collected in the context of the study "Immuno-transcriptomic profiling of blood and tumor tissue identifies gene signatures associated with immunotherapy response in metastatic bladder cancer". In this study, we investigated which are the local and systemic immune changes in an experimental model of muscle-invasive bladder cancer upon immunotherapy. The RNA-sequencing data have been used to produce the results presented in the study. Please refer to the study publication material and methods and the metadata file for details.</p>
MITO END-3: efficacy of Avelumab immunotherapy according to molecular profiling in first line endometrial cancer therapy
<p>Immunotherapy combined to chemotherapy significantly improves progression free survival compared to first line chemotherapy alone in advanced endometrial cancer, with a much larger effect size in microsatellite-instability high (MSI-H) cases. New biomarkers might help to select patients that may have benefit among those with a microsatellite-stable (MSS) tumor.</p> <p>Methods.</p> <p>In a pre-planned translational analysis of the MITO END-3 trial we assessed the significance of genomic abnormalities in patients randomized to standard carboplatin/paclitaxel without or with avelumab.</p> <p>Results.</p> <p>Out of 125 randomized patients, 109 had samples eligible for Next Generation Sequencing (NGS) analysis and 102 had MSI tested. According to The Cancer Genome Atlas (TCGA) there were 29 cases MSI-H, 26 MSS TP53 wild type (wt), 47 MSS TP53 mutated (mut), and one case with <em>POLE</em> mutation. Four mutated genes were present in more than 30 % of cases: <em>TP53</em>,<em> PIK3CA</em>,<em> ARID1A</em>,<em> PTEN</em>. Eleven patients (10 %) had a BRCA 1/2 mutation (5 in MSI-H and 6 in MSS). High TMB (≥ 10Muts/Mb) was observed in all MSI-H patients, in 4 out of 47 MSS/<em>TP53</em>mut, and in no case in the MSS/<em>TP53</em>wt category. The effect of avelumab on progression-free survival (PFS) significantly varied according to TCGA categories, being favorable in MSI-H and worst in MSS/TP53mut (P interaction=0.003); a similar non-significant trend was seen in survival analysis. <em>ARID1A</em> and <em>PTEN</em> also showed a statistically significant interaction with treatment effect, that was better in presence of the mutation (<em>ARID1A</em> P interaction=0.01; <em>PTEN</em> P interaction=0.002).</p> <p>Conclusion</p> <p>The MITO END-3 trial results suggest that <em>TP53 </em>mutation is associated with poor effect of avelumab, while mutations of <em>PTEN</em> and <em>ARID1A</em> are related to a positive effect of the drug in patients with advanced endometrial cancer.</p>
Figure 1 from: Zlatanova T, Arabadjiev J (2024) The prognostic role of markers of systemic inflammation in patients with metastatic lung cancer receiving immunotherapy: A comprehensive review of the literature. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e115558
Figure 1 Biological Hallmarks of Cancer, Source: Adapted from Hallmarks of Cancer: The Next Generation, Hanahan D., Weinberg R.A. , Cell, Volume 144, ISSUE 5, P646-674, March 04, 2011, https://doi.org/10.1016/j.cell.2011.02.013.
Dataset #2 related to article "NaCl enhances CD8+ T-cell effector functions in cancer immunotherapy"
<p><span>CD8<sup>+</sup> T cells control tumors but inevitably become dysfunctional. Ionic metabolism is emerging as a regulator of CD8<sup>+</sup> T cells in anti-tumor immunity. We show that sodium chloride (NaCl) counteracts T-cell dysfunction to promote cancer regression. NaCl supplementation during CD8<sup>+</sup> T-cell culture induced potent effector differentiation, IFN-</span><span>g</span><span> production and cytotoxicity while maintaining gene networks responsible for stem-like plasticity. Accordingly, adoptive transfer of tumor-specific T cells resulted in superior anti-tumor immunity in a humanized model. In mice, high-salt diet reduced growth of experimental tumors in a CD8<sup>+</sup> T cell-dependent manner, by inhibiting terminal differentiation, and by enhancing the effector potency of CD8<sup>+</sup> T cells. Mechanistically, NaCl enhanced glutamine consumption that was critical for transcriptional, epigenetic and functional reprogramming. In humans, CD8<sup>+</sup> T cells undergoing antigen recognition in tumors and predicting favorable response to checkpoint blockade immunotherapy resembled those induced by NaCl. Thus, NaCl metabolism is a major regulator of CD8<sup>+</sup> T-cell effector function, with potential translation in cancer immunotherapy.</span></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.